Dr. Marc Klapholz, MD

Dr. Klapholz practices at University Hospital in Newark, New Jersey, part of State of New Jersey.

Dr. Klapholz's NPI, 1063447829, was assigned on July 11, 2006. Dr. Klapholz graduated from Albert Einstein College of Medicine of Yeshiva University in 1986. Dr. Klapholz holds New Jersey license 25MA06249400.

Dr. Klapholz's primary practice is University Hospital, at 150 Bergen St, Newark, NJ 07103 in Essex County. The practice phone is (973) 972-4300.

Dr. Klapholz's primary practice is University Hospital in Newark, New Jersey, part of State of New Jersey. The medical group on file is University Neuro-Ophthalmology Associates. Dmand AI also links Dr. Klapholz to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Klapholz practices, 2 sites in all. Vendor and product names are available with a free account.

Cardiovascular disease is Dr. Klapholz's primary specialty in the NPI Registry, under taxonomy code 207RC0000X. Dr. Klapholz is licensed in New Jersey.

CMS data shows 54 Medicare services from Dr. Klapholz across 1 procedure code in 2023, all of them office visits, for 24 Medicare patients. Medicare paid $2,847 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 24 Medicare patients who saw Dr. Klapholz in 2024. The largest group is 65 to 74, with 11 patients. 75% of them have heart failure, and 75% have high blood pressure. Their average risk score is 2.29, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Klapholz's median patient age at 64, with 50% women.

In 2024, Dr. Klapholz wrote 1,091 Medicare Part D claims for 76 patients. 82% of them were for generic drugs. CMS names the drug for 867 of them, across 33 drugs with 11 or more claims each, at $1,152,504 in total drug cost. In 2023, CMS named 725 claims across 27 drugs.

Dr. Klapholz accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Coronary angioplasty and stenting: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 26 papers to Dr. Klapholz, published from 2012 to 2024. 2016 was the busiest year, with 6. The most frequent topics are Disease Progression, Heart Failure and Acute Coronary Syndrome. Dr. Klapholz has published most often in Minerva Cardioangiol. Dr. Klapholz's most frequent co-authors are Alfonso Hillman Waller, MD, Christine Marie Gerula, MD and Edo Kaluski, MD.

Dmand AI links Dr. Klapholz to 2 clinical trials, 2 of them phase 3 studies. Conditions studied include Limb-girdle muscular dystrophy, type 1B, Pulmonary Arterial Hypertension and Cardiomyopathy, Dilated.

CMS Open Payments shows 18 general payments to Dr. Klapholz from 5 drug and device companies from 2016 to 2022. Consulting fees make up the largest share, 81% of the total. Janssen Research & Development, LLC paid the most, $9,700.

Dr. Klapholz graduated from Albert Einstein College of Medicine of Yeshiva University in 1986.